Manufacturers Life Insurance Company, The Arcus Biosciences, Inc. Transaction History
Manufacturers Life Insurance Company, The
- $108 Billion
- Q3 2024
A detailed history of Manufacturers Life Insurance Company, The transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 30,328 shares of RCUS stock, worth $476,149. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,328
Previous 29,858
1.57%
Holding current value
$476,149
Previous $454,000
1.98%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding RCUS
# of Institutions
201Shares Held
51.7MCall Options Held
236KPut Options Held
141K-
Black Rock Inc. New York, NY9.76MShares$153 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.47MShares$85.9 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA3.48MShares$54.6 Million0.48% of portfolio
-
State Street Corp Boston, MA3.01MShares$47.3 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.44MShares$38.3 Million0.1% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.13B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...